Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$62.03 ▼ -0.58
(-0.93%)
MKT CAP: $9.85B • VOL: 1.71M
52W L $40 52W H $91
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$52
MEDIAN
$69
MEAN
$71
HIGH
$84
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PCVX TAPE
PCVX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $75.06 | $71.33 | 2025-02-14 | $56.45 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $78.16 | $73.20 | 2025-02-06 | $58.31 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $70.71 | $68.23 | 2025-01-29 | $59.55 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $63.27 | — | 2025-01-17 | $60.79 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $54.59 | $58.93 | 2025-01-09 | $55.21 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $73.82 | $64.51 | 2024-12-18 | $53.97 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $60.17 | $62.65 | 2024-12-04 | $57.69 | -4.3% | 48% | C |